Drug Profile
BB 2983
Alternative Names: GI 245402Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator British Biotech
- Developer British Biotech; GSK
- Class Antirheumatics
- Mechanism of Action Metalloprotease inhibitors; Peptide hydrolase inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammatory bowel diseases; Rheumatic disorders
Most Recent Events
- 10 Nov 1997 Discontinued-I for Inflammatory bowel disease in United Kingdom (PO)
- 09 Oct 1997 Discontinued-I for Rheumatic disorders in United Kingdom (PO)
- 17 Apr 1997 Phase-I clinical trials for Inflammatory bowel disease in United Kingdom (PO)